Pharmaceutical giant Bristol Myers Squibb (BMS) and tech leader Microsoft have announced a strategic digital health partnership aimed at a critical medical challenge: identifying lung cancer before it becomes terminal.
The initiative will integrate FDA-cleared radiology AI algorithms into the Microsoft Precision Imaging Network, a platform already utilized by more than 80% of U.S. hospitals. By automating the analysis of X-rays and CT scans, the AI is designed to flag subtle lung nodules that the human eye might miss, triaging patients for life-saving care at significantly earlier stages.
Lung cancer remains the top cause of cancer deaths in the U.S., accounting for approximately 125,000 deaths annually. A major hurdle in treatment is that more than half of patients with “incidental findings”—abnormalities found during scans for unrelated issues—are lost to follow-up.
The BMS-Microsoft collaboration addresses this by:
-
Automating workflows: Using AI to surface hard-to-detect nodules in daily radiologist workflows.
-
Patient tracking: Leveraging Microsoft’s clinical tools to ensure patients with flagged nodules remain in the care pathway.
-
Streamlining care: Guiding patients quickly toward precision therapies and optimal treatment plans.
A primary pillar of the partnership is bringing advanced diagnostics to medically underserved and rural communities. These populations often face higher mortality rates due to a lack of access to guideline-concordant screening.
“At BMS, health equity is not a standalone initiative—it is embedded in everything we do,” Andrew Whitehead, VP and head of Population Health at BMS said. “By bringing advanced AI tools to the front lines, together we will help to address health disparities in lung cancer.”
Because Microsoft’s radiology solutions are already “behind the scenes” in the majority of American healthcare delivery organizations, the barrier to implementation is low.
Peter Durlach, corporate VP at Microsoft Health and Life Sciences, noted that the technology allows clinicians to identify signs of cancer “often before [patients] are aware of any symptoms.”
